Cost analysis of drug treatment in hypertensive patients at social security health care family medicine units
Juan Figueroa-García, Víctor Granados-García, Ernesto Roldán-Valadéz, David Rojano‐Mejía, Jairo Enoc Cruz-Toledo, Silvia Palomo‐Piñón · Salud Pública de México · 2022
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Salud Pública de México · Instituto Nacional de Salud Pública · article · 2022
Abstract
OBJECTIVE: To estimate the increase of drug treatment costs associated with predictive factors of hypertensive patients in family medicine units. MATERIALS AND METHODS: A generalized linear model was employed to estimate costs with data from a microcosting costing study for a 1-year time horizon. Sources of dada were medical electronic files, phar-macy records and unitary prices updated to 2019. RESULTS: From a total of 864 patients older than 65 years were 67% and women 65%. Factors with most influence on mean drug treatment costs were diabetes, age and complications associ-ated with hypertension.
Mean annual cost of antihypertensive treatment was 61 dollars (CI95% 55,67) and median were 32 dollars (IQR 30,35) per patient. Incremental costs for diabetes were 23 dollars (CI95% 13,33) and 25 dollars (CI95% 5,45) in the group of ≥ 65 years. CONCLUSION: Diabetes, age and complications were the factors with largest influence on hypertension pharmacological costs.
Open the resolved locator · 10.21149/12972
Metadata licence: OpenAlex metadata (CC0)